Juan A. Sabater Net Worth

Insiders trading at Harmony Biosciences

Over the last 4 years, insiders at Harmony Biosciences have traded over 224,163,932$ worth of Harmony Biosciences stock and bought 514,681 units worth 12,537,009$ . The most active insiders traders include Holdings A/S Novo、Andreas Wicki、Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of 2,907,691$. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth 559,200$.

What does Harmony Biosciences do?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences executives and stock owners

Harmony Biosciences executives and other stock owners filed with the SEC include:

• John Charles Jacobs M.B.A.,
  Pres, CEO & Director
• Dr. Jeffrey M. Dayno M.D.,
  Chief Medical Officer
• Jeffrey Dierks M.B.A.,
  Exec. VP & Chief Commercial Officer
• Andrew Serafin J.D., M.B.A.,
  Exec. VP & Chief Strategy Officer
• Jeffrey S. Aronin,
  Founder & Non-Exec. Chairman
• Patricia L. Bank,
  Investor Relations Officer
• Nancy Leone,
  Head of Corp. Communications
• Tricia Glover,
  Chief Compliance Officer
• Christian Ulrich,
  Gen. Counsel
• Sharon Goldbach,
  Head of Facilities Operations & Exec. Admin.
• David Bradshaw,
  Head of Technical Operations
• Sandip S. Kapadia CPA, M.B.A.,
  Chief Financial Officer
• Holdings A/S Novo,
  10% owner
• Iv Pharma Holdings, Llc Val...,
  
• Fund Trust Ii Marshman,
  10% owner
• Andrew Serafin,
  CHIEF STRATEGY OFFICER
• Linda M Szyper,
  
• Antonio J. Gracias,
  
• R. Mark Graf,
  
• Eric L Motley,
  Director
• Jeffrey S Aronin,
  Director
• Jeffrey Dierks,
  CHIEF COMMERCIAL OFFICER
• John C Jacobs,
  PRESIDENT, CEO
• Jack Nielsen,
  
• Sandip Kapadia,
  CHIEF FINANCIAL OFFICER
• Jeffrey M. Dayno,
  PRESIDENT, CEO
• Gary Sender,
  
• Juan A. Sabater,
  
• Peter Anastasiou,
  
• Kumar Budur,
  CHIEF MEDICAL OFFICER